about
Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibodyConformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor SignalingSmall molecule proprotein convertase inhibitors for inhibition of embryo implantationActivity-modulating monoclonal antibodies to the human serine protease HtrA3 provide novel insights into regulating HtrA proteolytic activities.Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators.Unexpected mechanisms of action for a cytokine receptor-blocking antibody.Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites.Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362.Oncogenic protein interfaces: small molecules, big challenges.The βc receptor family - Structural insights and their functional implications.Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.Role of the β Common (βc) Family of Cytokines in Health and Disease.Aspartate aminotransferase: investigation of the active sites.Agonist binding and activation of the rat beta(1)-adrenergic receptor: role of Trp(134(3.28)), Ser(190(4.57)) and Tyr(356(7.43)).Computer-aided mapping of the beta-adrenoceptor. 1. Explanation for effect of para substitution on blocking activity at the beta-1-adrenoceptor.A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment.Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.Protein structure and computational drug discoveryEPO does not promote interaction between the erythropoietin and beta-common receptorsRepurposing the selective estrogen receptor modulator to suppress gastrointestinal cancer growthEvaluation of the predicted secondary structure of bacteriorhodopsin. Prediction of the bovine rhodopsin secondary structure and its sequence similarity with bacteriorhodopsinThe 'Q-band' absorption spectra of hematoporphyrin monomer and aggregate in aqueous solutionMolecular studies of alpha-2-adrenoceptor and catecholamine-insensitive imidazoline-receptor binding sites using [3H]-rilmenidine in rat brain and kidneyRole of beta-adrenergic receptor subtypes in lipolysisbeta(1)- and beta(2)-Adrenoceptor antagonist activity of a series of para-substituted N-isopropylphenoxypropanolamines[3H]Rilmenidine-labelled imidazoline-receptor binding sites co-localize with [3H]2-(benzofuranyl)-2-imidazoline-labelled imidazoline-receptor binding sites and monoamine oxidase-B in rabbit, but not rat, kidneyThe mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities
P50
Q27694580-1059E8EB-9B8C-4C7C-BE83-E4F9A23D3DC7Q27718099-F6707F60-C07B-4294-B66C-FFBEDDAAB032Q28535917-569AE409-4485-4D62-A3E3-26BEB7622198Q34232310-852E0210-9AF2-47C2-B288-66980B5CA856Q34416582-55D33BE5-C456-4314-8B6A-EEE3AEC9F6BEQ35064907-F267074D-6034-40ED-B492-FAC54FF2EC82Q36997749-D7E5DE88-CDF4-424D-BE9C-62400C2FCC0DQ37604483-FF12E13B-AD9A-4DC3-9AB9-738CB71221B9Q37621434-2E09DE31-F960-4E23-89FC-E9A0CDF19730Q38195457-D72597F6-5A10-48AF-8A46-C90BE544A456Q38486363-34B8AC11-F074-46BF-9D15-E3E75D02E5A2Q38836980-41C16226-C5BA-49DF-B6E9-FDED13A5E5B9Q39400885-70632B4E-4469-4775-BE62-6FE220D71C8CQ39440164-9E3AD96B-5F2A-4022-8176-6CA7E9C3A70FQ43860789-BC166971-6DEC-4FF9-B6CA-36F68E160160Q44994366-7369A047-7C1C-4691-BFF3-CD97E48C1A32Q45098097-5639B6B8-4524-41C9-9E13-EE0C57C39D91Q48158203-5561E9C4-5C1A-423B-9B3A-AA55C217FF9AQ50101355-E3B6A41A-4961-4152-BBAF-FFA33254E494Q51807022-9F91C5C7-8AF0-4F7C-B2EE-6EC23833E598Q57153638-A88C30DA-B0EF-4CEC-9220-7E4E3CA7ED9AQ57838055-B6CD3D06-5548-4D8D-B2EB-7DDA227ED73FQ64079323-21A95186-7C6F-4FF8-B17D-AE2B271BA8F7Q67916819-5AF178AF-FD4A-4D19-BCF2-598AC95F094CQ69604418-4FB69782-1568-49D1-B5CC-7E9CD3322104Q72674626-5B302FE8-0EA0-4D05-9970-44779A1D5063Q73744833-B818ECF9-7E2E-419B-AC0E-C5AA2DBA6E68Q73978169-5ACD9171-E68B-4991-86C4-6EDD4CA6B25EQ77676057-1D5C0BFC-C972-4B63-87DB-2017FBAB126DQ89403485-B5185D91-3456-4E9F-827F-481264258D7F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tracy L Nero
@ast
Tracy L Nero
@en
Tracy L Nero
@es
Tracy L Nero
@nl
type
label
Tracy L Nero
@ast
Tracy L Nero
@en
Tracy L Nero
@es
Tracy L Nero
@nl
prefLabel
Tracy L Nero
@ast
Tracy L Nero
@en
Tracy L Nero
@es
Tracy L Nero
@nl
P106
P1153
57191607604
P31
P496
0000-0002-3393-1843